CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing
Cannabis Bioscience International Holdings (CBIH) has filed a petition to include Alexis Bortell as a witness in the upcoming DEA hearing on marijuana rescheduling, scheduled for February 4th. Bortell, diagnosed with intractable epilepsy at age seven, found relief through CBD and THC after conventional treatments failed. Her alternatives were either Felbatol, a drug with serious side effects, or a risky brain surgery.
The company aims to demonstrate through Bortell's testimony that cannabis' Schedule I classification is inappropriate, as it implies no medical use. The current classification has Bortell's career opportunities in medical school and created barriers to accessing her medication, despite keeping her seizure-free for nearly a decade.
Cannabis Bioscience International Holdings (CBIH) ha presentato una petizione per includere Alexis Bortell come testimone nell'imminente udienza della DEA sulla riclassificazione della marijuana, in programma per il 4 febbraio. Bortell, diagnosticata con epilessia intrattabile all'età di sette anni, ha trovato sollievo attraverso il CBD e il THC dopo che i trattamenti convenzionali si sono rivelati inefficaci. Le sue alternative erano Felbatol, un farmaco con effetti collaterali gravi, oppure un intervento chirurgico al cervello rischioso.
L'azienda mira a dimostrare attraverso la testimonianza di Bortell che la classificazione della cannabis come Schedula I è inadeguata, in quanto implica l'assenza di utilizzo medico. L'attuale classificazione ha limitato le opportunità di carriera di Bortell nella scuola di medicina e ha creato barriere per accedere alla sua terapia, nonostante l'abbia mantenuta senza crisi per quasi un decennio.
Cannabis Bioscience International Holdings (CBIH) ha presentado una petición para incluir a Alexis Bortell como testigo en la próxima audiencia de la DEA sobre la reclasificación de la marihuana, programada para el 4 de febrero. Bortell, diagnosticada con epilepsia intratable a la edad de siete años, encontró alivio a través del CBD y el THC después de que los tratamientos convencionales fracasaran. Sus alternativas eran o Felbatol, un medicamento con serios efectos secundarios, o una riesgosa cirugía cerebral.
La empresa tiene como objetivo demostrar a través del testimonio de Bortell que la clasificación de la cannabis como Programación I es inapropiada, ya que sugiere que no tiene uso médico. La clasificación actual ha limitado las oportunidades de carrera de Bortell en la escuela de medicina y ha creado barreras para acceder a su medicación, a pesar de haberla mantenido libre de crisis durante casi una década.
캐나다 바이오사이언스 인터내셔널 홀딩스 (CBIH)는 2월 4일로 예정된 마리화나 재조정에 관한 DEA 청문회에서 알렉시스 보르텔을 증인으로 포함시키기 위한 청원을 제출했습니다. 보르텔은 7세에 난치성 간질 진단을 받았으며, 기존 치료법이 실패한 후 CBD와 THC를 통해 도움을 받았습니다. 그녀의 대안은 중대한 부작용이 있는 펠바톨 약물 또는 위험한 뇌 수술이었습니다.
회사는 보르텔의 증언을 통해 대마초의 1군 분류가 부적절하다는 것을 입증하고자 하며, 이는 의학적 사용이 없음을 의미합니다. 현재의 분류로 인해 보르텔의 의과 대학 진로에 제한이 생겼고, 거의 10년 동안 발작을 예방해 준 약물 접근에 장벽이 생겼습니다.
Cannabis Bioscience International Holdings (CBIH) a déposé une pétition pour inclure Alexis Bortell en tant que témoin lors de la prochaine audience de la DEA sur le reclassement de la marijuana, prévue le 4 février. Bortell, diagnostiquée avec une épilepsie réfractaire à l'âge de sept ans, a trouvé un soulagement grâce au CBD et au THC après l'échec des traitements conventionnels. Ses alternatives étaient soit Felbatol, un médicament aux effets secondaires graves, soit une chirurgie cérébrale risquée.
L'entreprise vise à démontrer par le témoignage de Bortell que la classification de la cannabis en tant que Classe I est inappropriée, car elle implique qu'aucune utilisation médicale n'est possible. La classification actuelle a limité les opportunités de carrière de Bortell dans les écoles de médecine et a créé des barrières à l'accès à son traitement, malgré le fait qu'elle soit restée sans crise pendant près d'une décennie.
Cannabis Bioscience International Holdings (CBIH) hat eine Petition eingereicht, um Alexis Bortell als Zeugin in der bevorstehenden DEA-Anhörung zur Neueinordnung von Marihuana, die für den 4. Februar angesetzt ist, zuzulassen. Bortell, bei der im Alter von sieben Jahren unkontrollierbare Epilepsie diagnostiziert wurde, fand Linderung durch CBD und THC, nachdem herkömmliche Behandlungen gescheitert waren. Ihre Alternativen waren entweder Felbatol, ein Medikament mit schweren Nebenwirkungen, oder eine riskante Gehirnoperation.
Das Unternehmen beabsichtigt, durch Bortells Aussage nachzuweisen, dass die Einstufung von Cannabis als Klasse-I-Droge unangemessen ist, da sie impliziert, dass keine medizinische Verwendung möglich ist. Die derzeitige Einstufung hat Bortells Karrieremöglichkeiten an der medizinischen Fakultät eingeschränkt und Barrieren für den Zugang zu ihrer Medikation geschaffen, obwohl sie nahezu ein Jahrzehnt lang anfallsfrei geblieben ist.
- None.
- None.
HOUSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (CBIH) continues its unwavering advocacy for cannabis as a legitimate medicine by formally petitioning to have Ms. Alexis Bortell, long-time cannabis advocate and patient, to serve as a witness in the upcoming DEA hearing on marijuana rescheduling.
Alexis Bortell has been a leading voice in the fight for medical cannabis access since being diagnosed with intractable epilepsy at the age of seven. After enduring years of ineffective treatments with conventional anti-epileptic drugs, her remaining options were: Felbatol (Felbamate), a drug with serious and potentially life-threatening side effects, including dependency and abuse, or a lobectomy, an invasive brain surgery with the risk of devastating outcomes such as memory loss, impaired motor function, and emotional disorders. Ultimately, she found lasting relief through a combination of CBD and THC, a treatment that has kept her seizure-free for nearly a decade. Her story underscores the tragic impact of cannabis’ Schedule I classification, which perpetuates stigma that has severely limited her career opportunities in medical school due to drug tests, dictates where she must live, and creates completely unnecessary barriers to accessing her life-saving medication.
“Alexis’ story is the reason why this reclassification should happen. From childhood to adolescence, Alexis has faced unimaginable suffering,” said Rosangel Andrades, CBIH R&D Director. “Shouldn’t our society prioritize protecting its children and youth rather than forcing them to fight for their right to survive? The stigma of a Schedule I classification not only denies access to essential medication but also criminalizes those who seek to live healthier, fuller lives.”
“We hope the judge will recognize Alexis as CBIH’s witness for the DEA Hearings, as her personal journey is a compelling testament to the undeniable medical benefits of cannabis. Her experience clearly demonstrates that cannabis can no longer be classified as a Schedule I drug, which inaccurately claims it has no proven medical use,” said Mr. John Jones, CBIH Treasurer and Director.
This moment marks a monumental chapter in history, and we must rise to meet it. At the upcoming hearing on February 4th, CBIH aims to spotlight the real-world consequences of cannabis prohibition on patients and their families. Alexis Bortell’s testimony could serve as a profound reminder of the human cost of outdated policies and the critical need for meaningful reform.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
FAQ
When is CBIH's DEA rescheduling hearing scheduled for?
Why is CBIH petitioning to include Alexis Bortell as a witness?
How long has Alexis Bortell been seizure-free using cannabis treatment?
What limitations has Schedule I classification created for Alexis Bortell?
